Clinical Trials on HPE in Germany

Total 33 results

German Cancer Research Center
University Hospital Heidelberg; National Center for Tumor Diseases, Heidelberg

Recruiting

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers (PANHPVAX)

HPV

Germany
Oryx GmbH & Co. KG

Completed

Immune Therapy of HPV-induced Cancers

HPV-induced Cancers

Germany
Oryx GmbH & Co. KG

Completed

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)

HPV-induced Cancers

Germany
University of Luebeck
EUROIMMUN Medizinische Labordiagnostika AG

Completed

HPV Infections, Cancer of the Vulva and Therapeutical Success

HPV | Human Papilloma Virus

Germany
University Hospital Tuebingen

Recruiting

Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants

Cervical Cancer | HPV Infection

Germany
Johannes Gutenberg University Mainz
Bayer; Maastricht University; University of Bonn; Siemens Corporation, Corporate... and other collaborators

Recruiting

VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE (VTEval)

Venous Thromboembolism (VTE) | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Germany
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Ruhr University of Bochum

Recruiting

DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections (HPV-VG1)

HPV Infection | Cervix Dysplasia

Germany
European Organisation for Research and Treatment...
Danish Head and Neck Cancer Group

Active, not recruiting

AF CRT +/- Nimorazole in HNSCC

Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers

Belgium, France, Poland, Australia, Germany, Netherlands, Switzerland
Alexion Pharmaceuticals

Completed

A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
Lisette Nixon
Stanford University; University of Leipzig; AdventHealth; UNICANCER; Princess Alexandra...

Recruiting

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) (PATHOS)

Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

Germany, United Kingdom, United States, Australia, France
Inari Medical

Active, not recruiting

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH)

PE - Pulmonary Embolism | PE - Pulmonary Thromboembolism

United States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
Shire

Completed

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Hereditary Angioedema (HAE)

Israel, Germany, Mexico, United States, Romania
Alexion Pharmaceuticals, Inc.

Enrolling by invitation

Registry of Patients With Hypophosphatasia

Hypophosphatasia (HPP)

United States, Italy, Russian Federation, Spain, United Kingdom, Germany, Canada, France, Saudi Arabia, Poland, Australia
Takeda

Completed

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis (INTEGRATED)

Hereditary Angioedema (HAE)

France, Germany, Austria, Greece
Shire

Completed

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Hereditary Angioedema (HAE)

United States, Germany, Hungary
CSL Behring

Recruiting

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Hereditary Angioedema (HAE)

United States, Germany, Israel, Australia, Canada
Shire

Completed

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

Hereditary Angioedema (HAE)

Germany, Spain, United Kingdom, France, Italy, Belgium
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II (ENABLE)

Hereditary Angioedema (HAE)

Germany, Switzerland, Spain, Israel, Italy, Austria, Portugal, Kuwait
BioCryst Pharmaceuticals

Completed

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (APeX-1)

Hereditary Angioedema (HAE)

Canada, United Kingdom, Germany, Spain, Australia, Hungary, Italy, Austria, North Macedonia, Denmark, Switzerland
BioCryst Pharmaceuticals

Completed

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Romania, Switzerland, United Kingdom
Shire
Takeda Development Center Americas, Inc.

No longer available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Angioedema | Hereditary Angioedema (HAE)

United States, Canada, Germany, Hungary, Spain
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
Shire

Completed

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Hereditary Angioedema (HAE)

United States, Canada, Australia, Austria, Colombia, Germany, Hungary, Israel, Italy, Spain
Shire

Completed

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Hereditary Angioedema (HAE)

Spain, Israel, United States, Hungary, Germany, Canada, Romania
BioMarin Pharmaceutical

Completed

Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency (KAMPER)

Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency

Sweden, France, Italy, Spain, Germany, Netherlands, Austria, Slovakia, Portugal
BioCryst Pharmaceuticals

Completed

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks (OPuS-2)

Hereditary Angioedema | HAE

France, United Kingdom, Germany, United States, Belgium, Hungary, Italy, Canada
BioCryst Pharmaceuticals

Completed

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE (APeX-2)

Hereditary Angioedema | HAE

United States, Austria, Canada, Czechia, France, Germany, Hungary, North Macedonia, Romania, Spain, United Kingdom
Shire
Dyax Corp.

Completed

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, Canada, Germany, Italy, Jordan, Puerto Rico, United Kingdom
Shire

Completed

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, United Kingdom, Germany, Canada, Italy, Jordan, Puerto Rico
Shire
Takeda Development Center Americas, Inc.

Recruiting

Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Hereditary Angioedema (HAE)

France, Austria, Australia, Spain, Czechia, Italy, United Kingdom, Germany, Israel, Ireland, Brazil, Denmark, Greece, Sweden
BioCryst Pharmaceuticals

Completed

A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

Hereditary Angioedema | Prophylaxis | HAE

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Switzerland, United Kingdom, United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Serbia, Slovakia, South Africa, Spain
Daiichi Sankyo, Inc.

Completed

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

France, United States, Japan, Denmark, Italy, Russian Federation, Czechia, Germany, India, Israel, Philippines, Taiwan, Ukraine, Australia, Austria, China, Argentina, Belarus, Belgium, Brazil, Canada, Chile, Estonia, Hungary, Korea, Republic... and more

Clinical Trials on HPE in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations